Shirley Siang Ning Tan

Shirley Siang Ning Tan

Auto-generated profile, based on publicly available information

Shirley Siang Ning Tan

Clinical Research Center, Sarawak General Hospital, Sarawak, Malaysia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2017 in Pharmacogenomics
Verified
Journal Article
Closed access
STShirley Siang Ning Tan
Shirley Siang Ning Tan
AFAlan Yean Yip Fong
Alan Yean Yip Fong
MMMelissa Mejin
Melissa Mejin
JGJerry Gerunsin
Jerry Gerunsin
KKKhai Liy Kong
Khai Liy Kong
TOTiong Kiam Ong
Tiong Kiam Ong
Background: Patients undergoing elective percutaneous coronary intervention (PCI) with drug-eluting stents (DES) who have impaired clopidogrel response, have a higher risk of subsequent major adverse cardiovascular events (MACE). Aim of the study: To establish the relationship between CYP2C19 genotype, clopidogrel responsiveness and 1–year MACE. Materials & methods: Aspirin/clopidogrel responses were assessed with Multiplate Analyzer and CYP2C19*2 allele by SpartanRx. Results: A total of 42.0% carried ≥1 CYP2C19*2 allele. Prevalences of aspirin and clopidogrel high on-treatment platelet reactivity (HPR; local cutoffs: 300 AU*min for aspirin and 600 AU*min for clopidogrel) were 11.5% and 19.8% respectively. In multivariate ana­lysis, clopidogrel HPR was found to be an independent predictor for 1–year MACE (adj HR: 3.48, p = 0.022 ). Conclusion: Having clopidogrel HPR could be a potentially modifiable risk factor guided by phenotyping.

18 March 2025 in Health Science Reports
Verified
Journal Article
Open access
STShirley Siang Ning Tan
Shirley Siang Ning Tan
LTLee Len Tiong
Lee Len Tiong
KWKung Yee Wong
Kung Yee Wong
MWMastulu Binti Wahab
Mastulu Binti Wahab
AFAlan Yean Yip Fong
Alan Yean Yip Fong
COChoo Huck Ooi
Choo Huck Ooi
Background and Aims: Malaysia, like many developing countries, is undergoing epidemiologic transition where non‐communicable diseases, including cancer, are emerging as a prevalent health burden. Sarawak is the largest state in Malaysia, located on the island of Borneo. Compiling region‐specific cancer statistics is crucial for future planning and implementation of effective cancer management strategies.Methods: This study utilized cancer data reported to the Sarawak State Health Department with a cancer notification form. Data was obtained from the State cancer database. Incidence, Age‐Standardized Rate, frequency, cumulative rate, and lifetime risk were calculated. The population included Sarawak residents only who were defined as Malaysian citizens as well as permanent residents living in Sarawak at the time of diagnosis.Results: Between years 2011–2015, there were a total of 10,320 cancer cases (47.3% male). The incidence rate was approximately 16.6 persons per 100,000 population per year. An increasing trend was observed in cancer incidence with increasing age. Ethnic distribution reported the highest incidence among the Chinese (male cases:36.2% and female cases:36.4%), followed by the Iban (male cases:26.9% and female cases:24.5%), and Malay (male cases:18.3% and female cases:22.0%). The three most common cancers in male were colorectal (15.4%), nasopharyngeal (14.8%), and trachea, bronchus, lung (14.0%) cancer. In females, the first three common cancers were breast (27.9%), cervix uteri (11.6%), and colorectal (9.8%). There were wide disparities among common cancers across genders, different age groups and ethnic groups.Conclusion: The lifetime risk of a Sarawakian to develop cancer by age 75 is 1 in 11 in females and 1 in 10 in males. This present study provided a framework for the status and trend of cancer in Sarawak. These findings will provide additional information to guide strategy and resource planning in improving cancer care in Sarawak.

21 August 2025 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
LMLim Msh
Lim Msh
TSTan Ssn
Tan Ssn
SJSulehan J
Sulehan J
JZJantan Z
Jantan Z
SASharifah Ashrina Wan Ali
Sharifah Ashrina Wan Ali
AYAugustin Y
Augustin Y

26 April 2022 in Journal of Asian Pacific Society of Cardiology
Verified
Journal Article
Open access
PDF file
STShirley Siang Ning Tan
Shirley Siang Ning Tan
KKKeng Tat Koh
Keng Tat Koh
AFAlan Yean Yip Fong
Alan Yean Yip Fong
Mohamad Adam BujangMohamad Adam Bujang
Mohamad Adam Bujang
LTLee Len Tiong
Lee Len Tiong
TOTiong Kiam Ong
Tiong Kiam Ong
Background: N-terminal pro-brain natriuretic peptide (NT-proBNP) provides prognostic information regarding the risk of death, acute heart failure and the development of AF in patients with acute coronary syndrome. While there are established cut-off values for the association between clinical risk assessment scores and in-hospital mortality, there is no clear cut-off value for NT-proBNP to guide risk stratification in patients with acute MI (AMI). Our study sought to evaluate the cut-off values of NT-proBNP in all-cause mortality post AMI and to compare with other available risk assessment scores. Methods: We conducted a multi-centre, prospective, observational study involving 411 patients admitted for AMI. Plasma NT-proBNP was assessed within 24 hours of admission. Results: One-year all-cause mortality occurred in 31 (7.6%) of 411 patients. NT-proBNP ≥404 pg/ml had an area under the curve of 0.66 (95% CI [0.54–0.77]; p=0.004) to predict all-cause mortality at 1 year (sensitivity: 80.6%; specificity: 36.9%; positive predictive value: 9.47%; negative predictive value: 95.89%). Using the Youden index, an NT-proBNP level ≥1,995 pg/ml was an independent predictor of all-cause mortality at 1 year (adjusted HR 2.6; 95% CI [1.3–5.5]; p=0.010), regardless of cardiovascular disease risk factors or revascularisation status. There were no significant differences among the predictive values of NT-proBNP, Thrombolysis in MI risk score, Global Registry of Acute Coronary Events risk score and left ventricular ejection fraction in predicting all-cause mortality at 1 year (p>0.05). Conclusion: NT-proBNP level ≥1,995 pg/ml measured within 24 hours of admission for AMI was associated with higher all-cause mortality at 1 year. Randomised controlled trials are needed to further validate the usefulness of NT-proBNP for risk stratification in patients with AMI.

6 February 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
STShirley Siang Ning Tan
Shirley Siang Ning Tan
ESEdmund Ui-Hang Sim
Edmund Ui-Hang Sim
TJTimothy Adrian Jinam
Timothy Adrian Jinam
MLMelissa Siaw Han Lim
Melissa Siaw Han Lim
CCCassandra Sheau Mei Chee
Cassandra Sheau Mei Chee
AFAlan Yean Yip Fong
Alan Yean Yip Fong
Direct oral anticoagulants (DOACs) are preferred for atrial fibrillation (AF) due to their efficacy and safety, though response variabilities raises concerns about fixed-dose regimens. This study investigates the association between ABCB1 and CES1 genetic polymorphisms with Dabigatran trough drug levels (DL), clotting time (CT), and clinical outcomes in a multiethnic Malaysian cohort. A total of 180 AF patients in Dabigatran were sequenced across the entire length of ABCB1 and CES1 genes using the Illumina MiSeq platform. Trough Dabigatran levels and clotting time were measured by LC-MS/MS and viscoelastic assay (Clotpro®), respectively. Patients were followed up for one year to assess major adverse cardiovascular and cerebrovascular events (MACCE). The mean dabigatran level was 34.7 ± 45.4 ng/ml (CV: 130%), and clotting time was 374.6 ± 207.9 s (CV: 55.5%). Trough levels were significantly correlated with clotting time (r = 0.663, p < 0.001). Multiple non-coding variants in ABCB1 and CES1 showed nominal associations (unadjusted p < 0.05) with drug level (35 SNPs) and/or clotting time (32 SNPs), although none remained statistically significant after false discovery rate correction. A total of 17 SNPs overlapped, and were associated with both. Overall, these findings suggest that non-coding regulatory variation may contribute to inter-individual variability in dabigatran pharmacokinetics and pharmacodynamics, but the results are exploratory and require replication in larger cohorts. This study highlights the importance of population-specific pharmacogenomic research for future investigations on personalized anticoagulation strategies.

7 September 2018 in Pharmacogenomics
Verified
Journal Article
Closed access
STShirley Siang Ning Tan
Shirley Siang Ning Tan
KKKeng Tat Koh
Keng Tat Koh
LTLee Len Tiong
Lee Len Tiong
TOTiong Kiam Ong
Tiong Kiam Ong
AFAlan Yean Yip Fong
Alan Yean Yip Fong
Aim: Recurrent thrombotic events still occur despite dual antiplatelet therapy in patient's post percutaneous coronary intervention (PCI)could be attributed to high on-treatment platelet reactivity. Methods: A 44-year-old male, who had staged PCI to left anterior descending (LAD) 2weeks after an anterior MI, with a drug-coated stent was readmitted with new anterior STEMI 35days later. Coronary angiogram revealed mid-stent thrombus in situ. He had further uncomplicated PCI. Platelet function testing and genotyping showed clopidogrel high on-treatment platelet reactivity and CYP2C19*3/*17 genotype. Ticagrelor was commenced. Results & conclusion: This case study is the first reported in Malaysia to document a patient with a CYP2C19*3/*17 genotype presenting with a stent thrombosis after an uncomplicated index PCI procedure.